Eli Lilly and Company (NYSE:LLY) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 95,665 shares of the company's stock after selling 3,905 shares during the period. Eli Lilly and Company comprises approximately 0.7% of Yousif Capital Management LLC's holdings, making the stock its 16th biggest position. Yousif Capital Management LLC's holdings in Eli Lilly and Company were worth $55,765,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. JGP Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company's stock valued at $1,074,000 after buying an additional 16 shares during the period. Walkner Condon Financial Advisors LLC boosted its stake in Eli Lilly and Company by 2.8% during the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company's stock valued at $334,000 after purchasing an additional 17 shares during the period. Patton Albertson Miller Group LLC boosted its stake in Eli Lilly and Company by 2.8% during the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company's stock valued at $335,000 after purchasing an additional 17 shares during the period. Valley Wealth Managers Inc. boosted its stake in Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company's stock valued at $688,000 after purchasing an additional 17 shares during the period. Finally, Sandy Cove Advisors LLC boosted its stake in Eli Lilly and Company by 0.8% during the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company's stock valued at $1,307,000 after purchasing an additional 17 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LLY. DZ Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Barclays boosted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research note on Wednesday, February 7th. Erste Group Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated an "overweight" rating and set a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday, April 15th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an "overweight" rating in a research report on Friday, March 15th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $728.05.

Eli Lilly and Company Trading Up 2.0 %

Shares of NYSE:LLY traded up $14.29 during mid-day trading on Tuesday, hitting $745.62. The stock had a trading volume of 2,041,595 shares, compared to its average volume of 3,051,032. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company has a market cap of $708.46 billion, a PE ratio of 128.56, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $370.68 and a 12-month high of $800.78. The company's 50 day moving average is $763.89 and its 200-day moving average is $664.05.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm's quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.09 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company's stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.